Top Line: Does systematic mediastinal lymph node staging affect radiation treatment plans for patients with locally-advanced NSCLC?
The Study: Guidelines often recommend pathologic mediastinal lymph node evaluation for locally-advanced NSCLC. However, the intent of EBUS staging after a positive PET is more to confirm the presence of nodal disease. This trial sought to determine if systematic sampling of multiple mediastinal stations, whether they were involved or not on PET, identified occult nodal disease that may have been missed with PET and targeted EBUS staging. On the single-arm SEISMIC trial 155 patients underwent staging with both PET and EBUS with systematic fine needle aspiration (FNA) nodal sampling (of any visualized nodes ≥0.6 cm at levels 2R, 2L, 4R, 4L and 7) for suspected locally-advanced NSCLC prior to radiation. Overall, 35 patients (23%) had PET(+) EBUS(-) nodes with 31 (20%) down-staged from cN2–3 to cN0–1, and 20 of these (12%) proceeded to surgery all with confirmed pN0-1 disease. If proceeding to radiation, PET(+) EBUS(-) nodes were generally still included in treatment volume given risk of false negative with FNA. On the other hand, 18 patients (12%) had PET-occult nodal disease confirmed on EBUS-FNA, and half of these (n=9) were contralateral N3 disease. This was more common among those with adenocarcinoma and/or, as expected, central tumors. Dosimetric comparisons of plans created with and without EBUS staging revealed only 10% of PET(-) EBUS(+) nodes would receive prescription dose when planning based on PET alone. The authors concluded: “Our findings strongly suggest that systematic lymph node sampling should be routinely considered in patients with locally advanced NSCLC being considered for radiotherapy, given the likelihood of improved locoregional control.” This was a single arm study, but it would have been interesting to see whether these PET-occult nodes would have been controlled with chemotherapy and maintenance immunotherapy or whether they are drivers of disease recurrence after chemoradiation.
TBL: This intriguing study reports more than one in ten patients with locally-advanced NSCLC have microscopic nodal disease identified with systematic mediastinal staging that is PET(-) and rarely covered with radiation prescription dose, though the clinical significance of this remains uncertain. | Steinfort, Lancet Resp Med 2024
The Study: Guidelines often recommend pathologic mediastinal lymph node evaluation for locally-advanced NSCLC. However, the intent of EBUS staging after a positive PET is more to confirm the presence of nodal disease. This trial sought to determine if systematic sampling of multiple mediastinal stations, whether they were involved or not on PET, identified occult nodal disease that may have been missed with PET and targeted EBUS staging. On the single-arm SEISMIC trial 155 patients underwent staging with both PET and EBUS with systematic fine needle aspiration (FNA) nodal sampling (of any visualized nodes ≥0.6 cm at levels 2R, 2L, 4R, 4L and 7) for suspected locally-advanced NSCLC prior to radiation. Overall, 35 patients (23%) had PET(+) EBUS(-) nodes with 31 (20%) down-staged from cN2–3 to cN0–1, and 20 of these (12%) proceeded to surgery all with confirmed pN0-1 disease. If proceeding to radiation, PET(+) EBUS(-) nodes were generally still included in treatment volume given risk of false negative with FNA. On the other hand, 18 patients (12%) had PET-occult nodal disease confirmed on EBUS-FNA, and half of these (n=9) were contralateral N3 disease. This was more common among those with adenocarcinoma and/or, as expected, central tumors. Dosimetric comparisons of plans created with and without EBUS staging revealed only 10% of PET(-) EBUS(+) nodes would receive prescription dose when planning based on PET alone. The authors concluded: “Our findings strongly suggest that systematic lymph node sampling should be routinely considered in patients with locally advanced NSCLC being considered for radiotherapy, given the likelihood of improved locoregional control.” This was a single arm study, but it would have been interesting to see whether these PET-occult nodes would have been controlled with chemotherapy and maintenance immunotherapy or whether they are drivers of disease recurrence after chemoradiation.
TBL: This intriguing study reports more than one in ten patients with locally-advanced NSCLC have microscopic nodal disease identified with systematic mediastinal staging that is PET(-) and rarely covered with radiation prescription dose, though the clinical significance of this remains uncertain. | Steinfort, Lancet Resp Med 2024

